Biosimilar Evidence in the United States
The first biosimilar was made available to patients in the United States six years ago in 2015. These life-saving treatments have altered how Americans give and receive care. Without biosimilars, the cost of biologics was expected to rise by 56 percent on average, limiting patients' access to treatment for patients. To ensure continuous access to the US market, bipartisan policy measures are required. Once these barriers are removed, the biosimilars market in the United States will be able to fully exploit biosimilars' true cost-saving potential.
Through this whitepaper, DelveInsight is representing current state of biosimilar in the U.S market. The Biosimilar is expanding therapeutic options in the USA, which is allowing the patients to start treatment with biologic medications sooner. But there are certain challenges faced by biosimilars to enter the United States market. To overcome with the challenges the U.S FDA are updating its policies to reduce the difficulties or barriers that biosimilars experience when entering the market. In the USA, the approved biosimilars are for nine reference products, these are filgrastim, pegfilgrastim, bevacizumab, trastuzumab, infliximab, epoetin alfa, rituximab, etanercept and adalimumab. Launch of these biosimilars make treatment more accessible to patients. Biosimilars are expected to break existing market share records in cancer treatment areas. These therapies are gaining market share at a much faster and greater rate than previously released biosimilars. Biosimilar producers and regulators in the United States are gaining expertise and confidence, and technological advancements, as well as this type of science-based flexibility that will help the biosimilars industry to grow in the United States market.
